Regeneron officer Murphy proposes $4.77M share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Regeneron Pharmaceuticals, Inc. (REGN) officer Andrew J. Murphy gave notice of a proposed sale of 5,011 common shares, with an aggregate market value of $4,773,278.16 and an approximate sale date of November 17, 2026. Murphy acquired the shares through a net exercise of stock options on November 16, 2026. The notice gives May 7, 2026, as the adoption date for the Rule 10b5-1 plan.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Net Exercise financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.